Lobular carcinoma in situ of left breast
ICD-10 D05.02 is a billable code used to indicate a diagnosis of lobular carcinoma in situ of left breast.
Lobular carcinoma in situ (LCIS) of the left breast is a non-invasive form of breast cancer characterized by the abnormal proliferation of lobular cells within the breast lobules. Unlike invasive breast cancer, LCIS does not invade surrounding breast tissue but is considered a marker for an increased risk of developing invasive breast cancer in either breast later in life. Patients with LCIS typically do not present with a palpable mass or symptoms, and diagnosis is often made incidentally during breast biopsies performed for other reasons. Surveillance protocols for patients diagnosed with LCIS include regular clinical breast examinations and annual mammograms, with some guidelines recommending MRI for high-risk patients. The risk of progression to invasive breast cancer is estimated to be about 20-30% over the next 30 years, necessitating careful monitoring and potential preventive measures, such as chemoprevention or prophylactic mastectomy, depending on individual risk factors and patient preferences.
Detailed pathology reports, treatment plans, and follow-up care notes.
Diagnosis of LCIS during routine screening, management of patients with a family history of breast cancer.
Documentation should clearly outline the rationale for surveillance strategies and any preventive measures discussed with the patient.
Clear imaging reports indicating findings and recommendations for follow-up imaging.
Mammography or MRI findings leading to biopsy for suspected LCIS.
Radiology reports should specify the findings that led to the diagnosis and any recommendations for further imaging.
Used when a biopsy is performed to confirm the diagnosis of LCIS.
Pathology report confirming LCIS and operative notes detailing the procedure.
Oncologists should ensure that the diagnosis is clearly documented in the operative report.
Lobular carcinoma in situ (LCIS) is a non-invasive breast condition where abnormal cells are found in the lobules of the breast. It is not considered breast cancer but indicates an increased risk for developing invasive breast cancer in the future.
LCIS is typically diagnosed through a breast biopsy, often performed after abnormal findings on a mammogram. It is usually asymptomatic and may be found incidentally.
Management of LCIS primarily involves regular surveillance with clinical exams and imaging. Some patients may consider preventive measures such as chemoprevention or prophylactic surgery, depending on their individual risk factors.
